SCHEMBL2912653

SCHEMBL2912653

Cc1ccc(NC(=O)C(C)C)cc1-c1ccc(C(=O)O)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IP6K1 Q92551 1/20 0.49
IP6K3 Q96PC2 1/20 0.49
IP6K2 Q9UHH9 1/20 0.49
ALDH1A1 P00352 6/20 0.49
KDM4E B2RXH2 3/20 0.49
GLA P06280 1/20 0.49
HPGD P15428 3/20 0.49
RAB9A P51151 3/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
HTT P42858 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
KMT2A Q03164 3/20 0.48
MAPK14 Q16539 7/20 0.47
HSD17B10 Q99714 3/20 0.46
NPC1 O15118 2/20 0.46
USP2 O75604 1/20 0.46
LMNA P02545 1/20 0.46
MAPK1 P28482 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
RXRA P19793 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2913317 0.85 MEN1 (0.59) ALDH1A1RAB9ASMN1; SMN2HTTNPSR1
SCHEMBL2912882 0.84 MAPK14 (0.62) ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2
SCHEMBL2912590 0.82 MAPK14 (0.50) MAPK14RXRA
SCHEMBL5124801 0.81 ALDH1A1 (0.52) ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2
SCHEMBL2913670 0.81 MEN1 (0.53) NPSR1KMT2AMAPK14LMNAL3MBTL1
SCHEMBL2348556 0.81 MAPK14 (0.67) ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2
SCHEMBL7278525 0.80 ALDH1A1 (0.71) IP6K1IP6K3IP6K2ALDH1A1HPGD
SCHEMBL2914161 0.78 MAPK14 (0.67) ALDH1A1KDM4EHPGDMAPK14HSD17B10
SCHEMBL2911571 0.78 MAPK14 (0.51) MAPK14RXRA
SCHEMBL2349750 0.78 MAPK14 (0.69) MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1940786-B1 BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C ARROW THERAPEUTICS LTD (GB) 2010-08-18 EP disclosed
US-20080255105-A1 Biphenyl Derivatives and Their Use in Treating Hepatitis C ARROW THERAPEUTICS LIMITED (GB) 2008-10-16 US disclosed
EP-1940786-A1 BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C Arrow Therapeutics Limited (GB) 2008-07-09 EP disclosed
WO-2007031791-A1 BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C ARROW THERAPEUTICS LIMITED (GB) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255105-A1 Biphenyl Derivatives and Their Use in Treating Hepatitis C NR4A1, NR0B1, NR1H4 IP6K1 4130/4885IP6K3 4065/4885IP6K2 4513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.